Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities' Views and Needs

被引:37
作者
Matos, Cristiano [1 ]
Harmark, Linda [2 ]
van Hunsel, Florence [2 ]
机构
[1] Univ Seville, Fac Pharm, Dept Pharmacol, C Prof Garcia Gonzalez 2, E-41012 Seville, Spain
[2] WHO, Collaborating Ctr Pharmacovigilance Educ & Patien, Netherlands Pharmacovigilance Ctr Lareb, Goudsbloemvallei 7, NL-5237 MH Shertogenbosch, Netherlands
关键词
PHARMACOVIGILANCE; CONSUMERS; AWARENESS;
D O I
10.1007/s40264-016-0453-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction Patient reporting of adverse drug reactions (ADRs) to spontaneous reporting systems can make a valuable contribution to pharmacovigilance. However, the implementation and promotion of patient reporting systems (PRSs) differ worldwide. Objective The objective of the study was to describe attitudes toward PRSs, and progress toward implementing such systems among national competent authorities participating in the World Health Organization Programme for International Drug Monitoring. Methods A web-based questionnaire was constructed based on qualitative interviews, and distributed through SurveyMonkey (R) to all countries listed on the World Health Organization Programme for International Drug Monitoring (n = 178) during November and December of 2015. Data were analyzed using descriptive statistics and Chi-square tests. Results A total of 143 valid questionnaires were received from 141 countries (79.2 %). A spontaneous reporting system for both healthcare professionals and patients was present in 58 countries (41.1 %). An official PRS to report ADRs directly was implemented in 44 countries (31.2 %) and in a pilot stage in five countries (3.5 %). Patients were not allowed to report in 34 countries (24.1 %). The reasons for not having an official PRS were mainly a lack of resources/budget (56.5 %) or a lack of information/education for patients (56.5 %). When analyzing the attitudes among the respondents toward a PRS, most acknowledge that the general public contributes to the detection or strength of drug safety signals (82.2 % agree or strongly agree) and with information that is not present in healthcare professional reports (80.7 % agree or strongly agree). For respondents, giving feedback to patients could be an incentive for patients to report more (80.8 % agree or strongly agree). To be able to further PRSs, guidelines on promoting a PRS efficiently to the general public (87.4 % agree or strongly agree), training courses/conferences (86.7 % agree or strongly agree), or a public list of Lareb's scientific publications (86.7 % agree or strongly agree) were the support measures most well accepted by the respondents. Conclusions Most countries accept ADR reports from patients by an official reporting system designed for patients or through the existing system for healthcare professionals. The main reasons for not having a PRS is financial restraints and a lack of information/education of patients. Attitudes toward a PRS are positive, but some countries fear that they will not be able to handle an increase in reports.
引用
收藏
页码:1105 / 1116
页数:12
相关论文
共 36 条
[1]   Comment on: "Adverse Drug Reaction Reporting by Patients: An Overview of Fifty Countries" [J].
Ahmad, Syed Rizwanuddin .
DRUG SAFETY, 2015, 38 (01) :109-110
[2]   Patient reporting of suspected adverse drug reactions: a review of published literature and international experience [J].
Blenkinsopp, A. ;
Wilkie, P. ;
Wang, M. ;
Routledge, P. A. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (02) :148-156
[3]   Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to? A Review of the New EU Legislation on Pharmacovigilance [J].
Borg, John-Joseph ;
Aislaitner, George ;
Pirozynski, Michal ;
Mifsud, Stephen .
DRUG SAFETY, 2011, 34 (03) :187-197
[4]  
Cohen J, 2013, Statistical power analysis for the behavioral sciences, DOI [10.4324/9780203771587, DOI 10.4324/9780203771587]
[5]  
Danish Medicines Agency, 2010, DAN MED AG ANN PHARM
[6]   Medicine and the Media Thyroxine: anatomy of a health scare [J].
Faasse, Kate ;
Cundy, Tim ;
Petrie, Keith J. .
BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 :20-21
[7]   Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain [J].
Fortnum, H. ;
Lee, A. J. ;
Rupnik, B. ;
Avery, A. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (02) :161-165
[8]   Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media [J].
Ghosh, Rajesh ;
Lewis, David .
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (12) :1845-1853
[9]   Patient-Reported Safety Information: A Renaissance of Pharmacovigilance? [J].
Harmark, Linda ;
Raine, June ;
Leufkens, Hubert ;
Edwards, I. Ralph ;
Moretti, Ugo ;
Sarinic, Viola Macolic ;
Kant, Agnes .
DRUG SAFETY, 2016, 39 (10) :883-890
[10]   ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems [J].
Harmark, Linda ;
van Hunsel, Florence ;
Grundmark, Birgitta .
DRUG SAFETY, 2015, 38 (04) :337-347